Insider · CIK 0001866746
Mahesh Krishnan
Files at HALO (HALOZYME THERAPEUTICS, INC.). First filing Jun 30, 2026, latest Jun 30, 2026.
In brief
Mahesh Krishnan files SEC Form 4 as director at HALO (HALOZYME THERAPEUTICS, INC.). Since Jun 30, 2026, Mahesh Krishnan has reported 0 open-market buys worth $0 and 1 open-market sell worth $548k, the latest filed on Jun 30, 2026.
A track record needs three past buys with six months of prices behind them; Mahesh Krishnan has 0, so none is measured yet.
The newest scored trade: sold $548k of HALO on Jun 29, 2026, filed Jun 30, 2026, scored 24 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $548k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HALO: HALOZYME THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | HALOZYME THERAPEUTICS, INC. | $548k 7,304 shares | -34% | +48% from low-5% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 29, 2026 | HALO HALOZYME THERAPEUTICS INC | 7,304 0.01% of outstanding | $548k | Jun 29, 2026 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | HALO HALOZYME THERAPEUTICS, INC. | MOption exercise Common Stock10b5-1 | +7,304 | $38.46 | $281k | 21,766 | Jun 30, 2026 |
| Jun 29, 2026 | HALO HALOZYME THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -7,304 | $75.00 | $548k | 14,462 | Jun 30, 2026 |
| Jun 29, 2026 | HALO HALOZYME THERAPEUTICS, INC. | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -7,304 | $0.00 | $0 | 1,500 | Jun 30, 2026 |
| May 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Common Stock | +3,796 | $0.00 | $0 | 14,462 | May 7, 2026 |
| May 5, 2026 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Option to Purchase Common Stockderivative | +6,040 | $0.00 | $0 | 6,040 | May 7, 2026 |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Common Stock | +4,165 | $0.00 | $0 | 10,666 | May 2, 2025 |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Option to Purchase Common Stockderivative | +5,750 | $0.00 | $0 | 5,750 | May 2, 2025 |
| Apr 25, 2024 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Common Stock | +6,501 | $0.00 | $0 | 6,501 | Apr 29, 2024 |
| Apr 25, 2024 | HALO HALOZYME THERAPEUTICS, INC. | AGrant or award Option to Purchase Common Stockderivative | +8,804 | $0.00 | $0 | 8,804 | Apr 29, 2024 |
Questions about Mahesh Krishnan
Answered from the filings on this page, as of the latest one.
Is Mahesh Krishnan buying or selling?
In the last 12 months Mahesh Krishnan reported 0 open-market buys worth $0 and 1 open-market sell worth $548k on SEC Form 4; the latest was sold $548k of HALO on Jun 29, 2026. Grants, option exercises and tax withholding are not counted.
How did Mahesh Krishnan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mahesh Krishnan has 0.
Where does Mahesh Krishnan file Form 4?
Mahesh Krishnan has filed Form 4 at HALO (HALOZYME THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.